Researcher find potential target for atherosclerosis
Researchers have found a new way to reverse atherosclerotic plaque formation at the early stages. In Nature Cardiovascular Research, Alma...
Novartis AG to buy immunology specialist Calypso Biotech BV
Upon closure, the US$425m take-over of the Amsterdam-headquartered Calypso Biotech NV, would give Novartis AG full commercialisation rights to...
Roche jumps ship on AC Immune
In recent trials, both Semorinemab, a monoclonal antibody (mAb) binding all forms of Tau, and Crenezumab, a mAb targeting multiple forms of misfolded...
Production process for cell-based coffee published
Given the high environmental costs of producing 10 million tonnes of coffee per year, scientists have been considering biotechnological production...
Vandria SA bags CHF18m in Series A financing
agSwiss Vandria SA said it will use the proceeds from a CHF18m Series A financing led by ND Capital and a syndicate of HNW private investors to...
GLP1 agonists: FDA investigates suicide risk
It is rare for the US Food and Drug Administration (FDA) to act more slowly than its European counterpart, the EMA. However, this is the case with...
Onera Health raises US$32m in Series C round
Existing investors Innovation Industries, Invest-NL, imec.xpand, BOM, and 15th Rock participated in the financing of Onera Health (Eindhoven) along...